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Abstract
BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision
algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine kinase
inhibitors (TKIs). Conventional Sanger sequencing is the method currently recommended to test BCR-ABL1 KD
mutations. However, Sanger sequencing has limited sensitivity and cannot always discriminate between polyclonal
and compound mutations. The use of next-generation sequencing (NGS) is increasingly widespread in diagnostic
laboratories and represents an attractive alternative. Currently available data on the clinical impact of NGS-based
mutational testing in CML patients do not allow recommendations with a high grade of evidence to be prepared.
This article reports the results of a group discussion among an ad hoc expert panel with the objective of producing
recommendations on the appropriateness of clinical decisions about the indication for NGS, the performance
characteristics of NGS platforms, and the therapeutic changes that could be applied based on the use of NGS in
CML. Overall, these recommendations might be employed to inform clinicians about the practical use of NGS in
CML.
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Background
The introduction of three generations of tyrosine kinase
inhibitors (first: imatinib; second: dasatinib, nilotinib,
and bosutinib; third: ponatinib) has dramatically changed
the management and long-term outcome of patients
affected by chronic myeloid leukemia (CML). Neverthe-
less, resistance has been observed [1–4]. In about one-
third of patients who experience resistance to first-line
therapy, and in up to 50% of patients who experience
resistance to second- or subsequent-line therapy, point
mutations in the ABL1 kinase domain (KD) that impair
TKI binding can be detected [5]. Mutations may arise at
critical contact points between the inhibitor and its
target or in key regions of the KD, namely the
phosphate-binding loop (P-loop), the catalytic cleft, or
the activation loop (A-loop) [5]. One of the most fre-
quent and most challenging mutations is a substitution
of threonine with isoleucine at residue 315 (T315I), the
so-called “gatekeeper residue” that impairs the binding
of imatinib and all second-generation TKIs, and may be
overcome only by ponatinib. Detection of a mutation
identifies patients at greater risk of subsequent relapse
[6]. In the past, mutations (especially the T315I and the
P-loop mutations G250E, Q252H, Y253H/F, E255K/V)
had also been associated with significantly shorter
progression-free and overall survival [7–13]. In more re-
cent times, a negative prognostic impact has not been
observed in all studies [14], suggesting that the expanded
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drug armamentarium and the wider and wider use of
mutation testing in routine practice have been beneficial.
Indeed, each TKI has its own spectrum of sensitive and
insensitive mutations, and the type of mutation detected
may, nowadays, drive the choice of TKI to use after fail-
ure of first or subsequent lines of treatment (Table 1)
[5]. Early identification and quantitative monitoring of
mutant BCR-ABL1 subclones displaying resistance to
TKIs are thus important tasks for optimal management
of patients with CML.
Conventional Sanger sequencing is the currently rec-
ommended method for diagnostic BCR-ABL1 KD muta-
tion screening [16]. However, Sanger sequencing has
limited sensitivity (it cannot robustly identify mutations
present in less than 15–20% of transcripts) and, in many
cases, cannot provide clear discrimination between poly-
clonal and compound mutations [17].
Various next-generation sequencing (NGS)-based ap-
proaches facilitating sensitive detection and quantitative
monitoring of BCR-ABL1 KD mutations have recently
been described. They are able to detect and quantify any
sequence variation in BCR-ABL1 transcripts down to 1%
abundance and resolve the clonal architecture in the ma-
jority of cases harboring multiple mutations [18–20].
However, the broad clinical implementation of NGS for
BCR-ABL1 KD mutation testing has so far been ham-
pered by a series of issues, including limited availability
due to the high capital investment required to acquire
an instrument, and the current costs of the tests, which
may not be regarded as readily affordable for routine
diagnostic monitoring. Additionally, the currently avail-
able data on NGS-based BCR-ABL1 mutational testing
in CML patients who experienced resistance to treat-
ment have not yet been used to formulate recommenda-
tions on its utilization in clinical practice.
The objective of this project was to produce consensus-
based recommendations on the appropriateness of the
clinical decisions concerning the indications of NGS in
CML, the performance characteristics of NGS platforms,
and the therapeutic changes that could be applied based
on the results of NGS analysis.
Brief overview of NGS methodologies
The term “NGS” refers to different chemistries and plat-
forms that use different strategies to perform the same
series of tasks. Briefly, the pool of DNA molecules to be
sequenced (usually termed “library”: may be either frag-
mented genomic DNA or cDNA, or amplicons) need to
be physically isolated in space and clonally amplified by
polymerase chain reaction. Next, the instrument per-
forms massively parallel sequencing of each individual
molecule, yielding millions of sequence reads in a few
hours. Key features of NGS are thus the high throughput
and the clonal nature of sequence analysis. The high
throughput can be exploited to cover whole genomes, or
exomes, or transcriptomes in a single sequencing run, or
to focus on a panel of genes or genetic regions of inter-
est, that will be sequenced hundreds or thousands of
times, thus achieving high sensitivity. The latter cur-
rently represents the main diagnostic application of NGS
and is frequently referred to as “deep” or ultra-deep
sequencing’. For a more detailed technical overview of
NGS methodologies, see Yohe S and Thyagarajan B,
2017 and Muzzey D et al., 2015 [21, 22].
Methods
An Expert Panel (hereafter referred to as the Panel)
composed of Italian physicians and biologists was se-
lected for their individual expertise in research and clin-
ical practice in the management of CML and assembled
Table 1 List of BCR-ABL1 KD mutations poorly sensitive to imatinib, dasatinib, nilotinib, bosutinib, and ponatinib based on the
integration of published studies (2001–2018) reporting the mutation status of TKI-resistant patients and experimental data
Mutations poorly sensitive
to imatinib
M237V, I242T, M244 V, K247R, L248V, G250E, G250R, Q252R, Q252H, Y253F, Y253H, E255K, E255V,
E258D, W261L, L273M, E275K, E275Q, D276G, T277A, E279K, V280A, V289I, V289I, V289A, E292Q, E292V,
I293V, L298V, F311L, F311I, T315I, F317L, F317V, F317I, F317C, Y320C, L324Q, Y342H, M343T, A344V,
A350V, M351T, E355D, E355G, E355A, F359V, F359I, F359C, F359L, D363Y, L364I, A365V, A366G, L370P,
V371A, E373K, V379I, A380T, F382L, L384M, L387F, L387V, M388L, H396R, H396P, H396A, A397P, S417F,
S417Y, I418S, I418V, A433T, S438C, E450K, E450G, E450A, E450V, E453G, E453A, E453K, E453V, E453Q, E459K,
E459V, E459G, E459Q, M472I, P480L, F486S
Mutations poorly sensitive
to dasatinib
V299L, T315I, T315A, F317L, F317V, F317I, F317C
Mutations poorly sensitive
to nilotinib
Y253H, E255K, E255V, T315I, F359V, F359I, F359C
Mutations poorly sensitive
to bosutiniba




aIn contrast to the other second-generation TKIs, there is still limited data available on mutations associated with clinical resistance to bosutinib in vivo. In
vitro data suggest that the E255K and, to a lesser extent, the E255V might be poorly sensitive to bosutinib [15]
TKI tyrosine kinase inhibitor
The most frequent imatinib-resistant mutations are highlighted in boldface
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in May 2018. During an initial meeting held the follow-
ing month, the outline of the project was discussed, and
the topics that form the structure of the present docu-
ment were decided. Key questions were selected through
a series of questionnaires, and each panelist drafted
statements that addressed one or more questions, while
the remaining panelists scored their agreement with
those statements and provided suggestions for modifica-
tions. Finally, the Panel convened for a consensus con-
ference that was held in Milan, Italy, in November 2018.
At this conference, final proposals were given using the
nominal group technique [23], by which participants
were first asked to comment in a round-robin fashion
on their disagreements with the proposed issues and
then to vote for a final statement.
Results
A summary of the recommended indications for the use
of NGS testing in CML proposed by the Panel is pre-
sented in Table 2.
Indications for the use of NGS testing in chronic-phase
(CP) CML
Approximately one-third of CP CML patients with pri-
mary or acquired resistance to first or second-generation
TKIs harbor mutations in the BCR-ABL1 KD [6]. Such
mutations are not induced by TKIs. The selective pressure
exerted by TKIs selects for mutations that occur by
chance at resistance-causing residues at any time during
therapy. Mutations represent a hallmark of patients at
higher risk of acquiring further mutations and of relapse
on second- or subsequent-line of therapy [24–26]. No ro-
bust evidence has conclusively shown that mutations may
already be detectable at diagnosis in CP patients, even
when using highly sensitive methods. A recent study com-
bining high-resolution Duplex Sequencing and computa-
tional simulations has indeed suggested that, because of
the low number of leukemia-initiating cells, CP CML is
very unlikely to harbor resistant mutations at the time of
diagnosis and, regardless, these would be well below the
detection limit of NGS [27].
The detection of BCR-ABL1 mutations in TKI-treated
patients may represent a biological hallmark of disease pro-
gression: cells from CP patients harboring mutations have
gene expression profiles superimposable to those from blast
crisis (BC) patients [28]. In a study in which 319 CP CML
patients were routinely monitored for mutations by Sanger
sequencing regardless of response status, the identification
of mutations even without evidence of imatinib resistance
was found to be highly predictive for loss of complete cyto-
genetic response (CCyR) and progression to advanced
phase [8]. NGS was found to anticipate the detection of
emerging resistant mutants from 2 to 11months earlier
than Sanger sequencing and, in some instances, could re-
veal TKI-resistant mutations at the time of major or deeper
molecular responses [29]. In another backtracking study,
the highly resistant T315I substitution was found to be de-
tectable on average 3months earlier than with Sanger se-
quencing [30]. A more recent study performed in an
unselected series of 121 CML patients who were systemat-
ically screened using NGS, irrespective of their response to
first-line TKI therapy, showed that detection of a mutation
by NGS was associated with significantly worse outcomes
[31]. Patients who developed a KD mutation had a lower
cumulative incidence of CCyR and major molecular
response (MMR) compared to patients without mutations.
Patients with mutations also had worse 5-year progression-
free survival and a higher 5-year cumulative incidence of
progression compared to patients without mutations [31].
At present, however, both the European LeukemiaNet
(ELN) recommendations and the National Comprehensive
Cancer Network (NCCN) guidelines anchor KD mutation
testing to the lack of optimal response [16, 32, 33]. A more
accurate picture of BCR-ABL1 mutation status at the time
of failure, when therapy has to be changed, may help in
selecting the most active TKI. In imatinib-resistant patients
who failed second-line dasatinib or nilotinib therapy be-
cause of the selection of a BCR-ABL1 KD mutation, the
same mutation could retrospectively be tracked by NGS
back to the time of imatinib failure [29, 34, 35]. The
advantage of a more sensitive approach at the time of
switching to second-line TKI therapy in imatinib-resistant
patients had already been shown by Parker et al. using a
Table 2 Summary of the indications for the use of next-
generation sequencing (NGS) for BCR-ABL1 KD mutation testing
in chronic myeloid leukemia (CML)
Indications for the use of NGS testing in chronic phase CML
- in patients with failurea response to TKI therapy, irrespective
of the TKI
- in patients with warninga response to TKI therapy, irrespective
of the TKI
Indications for the use of NGS testing before allogeneic stem cell
transplant (allo-SCT)
- BCR-ABL1 KD mutation status by NGS testing before allo-SCT
may provide useful information regarding when post-transplant
TKI therapy should be reinstated. Patients who do not have
BCR-ABL1 KD mutation results by NGS available at the time of
transplant should be testedb
Indications for the use of NGS testing in advanced CML phases
- all patients with advanced phase (AP or BC) either at diagnosis
or during therapy
Indications for the use of NGS testing after TKI therapy discontinuation
- in patients relapsing after a TFR attempt if they fail to re-achieve
MMR within 3–6 months after TKI re-treatment
aIt has to be noted that, at present, failure and warning definitions for third-
line and beyond are lacking
bProvided that BCR-ABL1 transcript levels are sufficient, i.e., > 0.1%IS
AP accelerated phase, BC blast crisis, MMR major molecular response, TFR
treatment-free remission, TKI tyrosine kinase inhibitor, IS International Scale
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mass spectrometry-based approach of mutation analysis
[36, 37]. In the case of a clinical response classified as
“warning,” more accurate and frequent monitoring is rec-
ommended in order to allow a prompt change in therapy
[33]. In this clinical setting, emerging resistant clones could
be present below the detection limit of Sanger sequencing
and might thus not be identified in a timely manner,
ultimately leading to treatment failure. Indeed, in an-
other “backtracking” study performed in 51 CP CML
patients who had acquired TKI-resistant mutations
on second-line therapy, the first detection by NGS
occurred at the time of a “warning” response in
many cases [38]. Unfortunately, however, there are
currently no formal definitions of failure and warn-
ing beyond second-line, although an update of the
2013 ELN recommendations is planned. Patients on
second-line therapy may harbor multiple mutations.
In these cases, NGS can define whether such muta-
tions are compound or polyclonal, guiding proper
clinical management - because compound mutants
and, in particular, those including the T315I have
been predicted to be highly resistant to all second-
generation TKIs [39, 40].
Consensus statements
Neither conventional Sanger sequencing nor NGS for
BCR-ABL1 KD mutation testing are indicated in patients
with CP CML at diagnosis, before the start of first-line
TKI therapy.
BCR-ABL1 KD mutation testing by NGS is indicated
in CP CML after first-line TKI therapy in patients with a
“warning” response, regardless of the generation of TKI
used for first-line therapy. In these patients, NGS may
detect emerging resistant mutants earlier than Sanger se-
quencing and could allow a timely therapeutic switch,
when appropriate.
BCR-ABL1 KD mutation testing by NGS is indicated
in CP CML after first-line TKI therapy in patients with a
“failure” response, independently from the generation of
TKI used for first-line therapy. In these patients, NGS
could detect a complex pattern of mutations, including
low-level and/or compound mutations, and could allow
more individualized therapeutic decision-making.
BCR-ABL1 KD mutation testing by NGS is also in-
dicated in case of a “warning” or “failure” response
after second-line TKI therapy. In this situation, the
identification of mutations not detectable by Sanger
sequencing could allow a more appropriate change of
therapy.
The panel agreed that, at present, it is not possible to
provide recommendations on NGS testing in patients
who are receiving third- or later-line TKI therapy due to
the lack of definitions of “optimal,” “warning” and “fail-
ure” responses in that setting.
Indications for the use of NGS testing before allogeneic
stem cell transplant
Allogeneic stem cell transplant (allo-SCT) is still the
only available treatment that is considered as a curative
option, although the high procedural morbidity and
mortality remain a major deterrent. The current indica-
tions for allo-SCT in CP CML are as follows: failure of
nilotinib or dasatinib in the first line or failure of two
TKIs or evidence of T315I mutation [33]. The majority
of patients who underwent an allo-SCT in the European
Group for Blood and Marrow Transplantation (EBMT)
database were treated in the pre-ponatinib era, limiting
the possibility of establishing whether specific settings,
such as CP patients with T315I mutation or patients
resistant to a frontline second-generation TKI, are in
fact real candidates for this procedure. Indeed, allo-SCT
is recommended for all BC patients and for accelerated
phase (AP) patients who do not achieve an optimal re-
sponse [33, 41, 42].
The detection of low-level mutations after TKI failure
may become important in opting for stem cell transplant
procedure in the presence of a T315I mutation or when
multiple mutations are present. In the latter case, it will
be important to distinguish between compound and
polyclonal mutations with or without T315I. Relapse
after allo-SCT in CML is observed in 20 to 40% of
patients. In this setting, a continued regular long-term
longitudinal monitoring of quantitative BCR-ABL1 tran-
script levels post-transplant is crucial to anticipate the
occasional late-relapsing patients. The detection of BCR-
ABL1 transcripts in the first few months after transplant
seems not to be associated with a worse long-term out-
come. Furthermore, it has been shown that persistence
of very low levels of residual disease (BCR-ABL1 <
0.1%IS) detectable up to 10 years post-transplant has less
implication for relapse [43]. It has been suggested that
pre-transplant mutation analysis should be considered
when selecting a TKI for post-transplant prophylaxis,
based on the observation that the majority of resist-
ant mutations are still detectable after transplantation
and that patients often relapse with these mutant clones
despite receiving TKI therapy [44, 45].
Consensus statements
Although the decision to direct a patient to SCT is based
on his/her past clinical history of treatment failure, the
Panel recognized that the knowledge of pre-transplant
mutation status might be useful should TKI treatment
be restarted afterward. Thus, cases who did not undergo
NGS testing at the last treatment failure before trans-
plant should be analyzed, provided that BCR-ABL1 tran-
script levels make it feasible (e.g., are > 0.1%IS).
In case of disease relapse or failure to achieve an opti-
mal response with the re-administration of TKIs after
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allo-SCT, the recommended method of assessing BCR-
ABL1 KD mutation status remains Sanger sequencing
because no studies have yet investigated the clinical
value of low-level mutations in this setting. However, it
can reasonably be assumed that low-level mutations may
display the same kinetics of selection under TKI pres-
sure. The Panel agreed that the use of NGS testing for
BCR-ABL1 KD mutations in this setting should be
investigated.
Indications for the use of NGS testing in advanced CML
phases
Fewer than 5% of patients with CML are diagnosed in ad-
vanced disease, as AP or BC. Furthermore, a small propor-
tion of patients (5–6%) diagnosed in CP become resistant
and progress to advanced disease during treatment [46, 47].
One of the hallmarks of AP and BC is genetic instability,
which fosters the development of additional cytogenetic ab-
normalities and point mutations, including mutations in
the BCR-ABL1 KD [48–50]. Accordingly, the frequency of
BCR-ABL1 KD mutations has been reported to be much
higher in AP/BC patients (70–80%) than in CP patients
[51]. Additionally, BC patients frequently harbor multiple
mutations whose clonal relationship cannot always be easily
established by Sanger sequencing, unless a cumbersome
process of cloning and sequencing is undertaken [39]. In
BC patients, NGS has shown that different Ph + subpopula-
tions may follow different routes to escape TKI inhibition,
so that mutants detectable by Sanger sequencing may coex-
ist with mutants detectable only by NGS [34]. A series of
early case reports has also suggested that mutations may be
detectable already at the time of diagnosis in patients who
present in AP/BC, especially when highly sensitive assays
are used [52–54].
Consensus statements
In patients with advanced-stage CML at diagnosis or in
patients who progress to AP/BC during therapy, the use
of NGS testing for BCR-ABL1 KD mutations could re-
veal both single mutations, especially T315I, and low-
level compound mutations more frequently than Sanger
sequencing. The Panel agreed that searching for BCR-
ABL1 KD mutations by NGS testing is indicated to allow
for personalized therapy planning.
Indications for the use of NGS testing after TKI therapy
discontinuation
Treatment discontinuation, commonly referred to as
“treatment-free remission” (TFR), is an appealing goal of
CML therapy. CML patients with a sustained and stable
deep molecular response (MR4 or greater) for more than
2 years are possible candidates for discontinuation. Since
the first prospective TFR trial (the STIM-1 study in
2007), more than 2000 CML patients worldwide have
pursued TKI discontinuation in a clinical trial [55]. Re-
ports from these studies (recently reviewed in [56]) have
demonstrated that not all patients eligible for TFR will
maintain a deep molecular response once TKI therapy
has been discontinued. Invariably, 40–60% of patients
will lose their molecular response (defined as the loss of
MMR) and will have to resume therapy. The long-term
follow-up is consistent across several studies, including
patients treated with second-generation TKIs. In the ma-
jority of patients, relapses occur rapidly within 6months
after treatment discontinuation [56].
Patients in molecular relapse who promptly restart TKI
therapy remain responsive to re-treatment and rapidly re-
gain MMR after 2–3months, and deeper responses there-
after [57]. So far, only one case has been reported to have
developed a mutation at the time of molecular relapse [58].
Consensus statement
While NGS testing for BCR-ABL1 KD mutations has no
additional value in patients losing deep molecular re-
sponse after TKI discontinuation, it is indicated in patients
relapsing after a TFR attempt if they fail to re-achieve
MMR within 3–6months after TKI re-treatment.
Impact of NGS on therapeutic decisions
The recent study by Kizilors et al. in an unselected series
of patients systematically analyzed by NGS regardless of
their response to TKI therapy showed that patients posi-
tive for mutations by NGS have significantly worse out-
comes in terms of loss of MMR and CCyR and
probability of progression [31]. In that study, a threshold
of 3% was established based on a thorough methodo-
logical validation, which also led to ISO 15189 accreditation
of the assay [31]. In the NGS studies in TKI-resistant pa-
tients published so far, no low-level mutation known to be
resistant to the TKI the patient was receiving failed to
undergo clonal selection [29–31, 34, 35, 38]. Some studies
even included a control group of patients who responded
to therapy or who relapsed with no evidence of mutation
selection by Sanger sequencing [30, 35, 38], and in these
groups, no low-level mutation resistant to the TKI in use
were detected. In all of these studies, the lower detection
limit of NGS was set to 1–3% [29–31, 34, 35, 38, 59–62]. In
the prospective multicenter study “NEXT-in-CML,” a lower
detection limit of 3% was chosen after a control round
aimed at testing inter-laboratory reproducibility, showing
that in between 1 and 3% of variant frequency, some false
positive and false negative mutation calls may occur [63].
Additional studies will be needed to confirm a threshold
showing the relevance and robustness at both the technical
and clinical levels. In particular, the relevance of low-level
mutations for whom inconclusive or no in vitro or in vivo
sensitivity data are available is still unknown, and whether
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they can represent at least a marker of greater genetic in-
stability is under investigation.
Consensus statements
In general, the interpretation of the results of BCR-ABL1
KD mutation testing by NGS and the consequent clinical
decisions should involve both biologists and clinicians
expert in CML biology and treatment.
The Panel agreed that whether a positive mutation re-
sult by NGS testing should lead to an immediate change
of treatment depends on the level of non-optimal re-
sponse to TKIs, the type and level of mutation(s) detected
by NGS, and clinical considerations as to the suitability of
therapeutic alternatives for each individual patient.
The Panel argued that the greatest utility of BCR-ABL1
KD mutation testing by NGS is in CP CML patients with
a “failure” or “warning” response. In the latter setting, the
detection of any mutation known to be associated with re-
sistance to the TKI the patient is receiving at a level > 3%
should be strongly considered for a change of therapy; if
the mutation level is between 1 and 3%, testing a subse-
quent sample in 1month is recommended in order to
check for mutation kinetics. An increase in mutation bur-
den should trigger a change of therapy.
Performance characteristics of NGS testing in CML
TKI-resistant mutations have been reported all over the
KD [6]. Mutations outside the KD have been investigated
and described in only a single study [64], but their clinical
relevance, if any, is unknown. There are currently no Euro-
pean Conformity (CE)-marked for in vitro diagnosis (CE-
IVD) or Food and Drug Administration (FDA)-approved
commercial kits available for NGS-based BCR-ABL1 KD
mutation testing. The so-called “myeloid panels” include
the ABL1 exons coding for the KD, but DNA-based muta-
tion screening would mainly have untranslocated ABL1 as
a substrate, thus dangerously “diluting” mutations down to
a level that might be undetectable even by NGS. Some
studies have reported the setup and application of in-
house-developed protocols for BCR-ABL1 KD mutations
screening implemented on different NGS platforms [29–31,
34, 35, 38, 60–62].
The results of these studies suggest that NGS-based
BCR-ABL1 KD mutation screening is technically feasible in
expert laboratories and may provide accurate and reprodu-
cible results even down to variant frequencies of 1%. How-
ever, inter-lab reproducibility is equally fundamental for
diagnostic accuracy and homogeneity of patient manage-
ment. National or international expert networks exist that
have played, and will continue to play, a key role in the
standardization and harmonization of diagnostic tools. For
example, at the European level, the “EUTOS (European
Treatment and Outcome Study) for CML” initiative, that
over the past decade has been running regular control
rounds for real-time quantitative polymerase chain reaction
(PCR)-based molecular response monitoring, has recently
undertaken the first control round of NGS-based BCR-
ABL1 KD mutation screening.
Consensus statements
Any NGS-based BCR-ABL1 KD screening assay should
have three mainstays:
a) RNA from peripheral blood buffy coat as a template.
Any in-house or commercial method of RNA extraction
may be used provided that it ensures at least one micro-
gram of high-quality RNA;
b) Selective analysis of the ABL1 KD derived from the
fusion BCR-ABL1 allele. This may be accomplished
using two alternative forward primers, either on BCR
exon 1 (for the e1a2 breakpoint; p190) or on exon 13
(for the b2a2 and b3a2 breakpoints; p210) and a com-
mon reverse primer on ABL1 exon 10. The resulting
amplicon may either be used as a template for a nested
PCR or may be enzymatically fragmented, provided that
the resulting amplicons or fragments are of adequate
length, as detailed below;
c) Amplicon/fragment length not shorter than 300
base pairs (bp; excluding adapters and indexes). Accord-
ingly, sequencing chemistry and cycles producing reads
shorter than 400 bp are not recommended, since this
would be of limited value for the detection of compound
mutations. The minimal region to be screened for muta-
tions must include an mRNA sequence (reference:
Genbank accession no. NM_005157.5) corresponding to
amino acids 235 through 498 of the ABL1 1a protein
isoform (KD). Mutations outside this region, if detected,
should not be reported.
The minimum recommended depth of coverage is
1000×; better if greater. Until commercial kits are avail-
able, each individual laboratory will be responsible for
the optimization of assay conditions and will have to
carefully assess accuracy, precision (repeatability), and
analytical sensitivity.
Given the inherent differences between NGS platforms,
protocols, and bioinformatics tools, specific recommenda-
tions on ranges and thresholds cannot be provided. It is
recommended that the performance requirements for
each individual assay be established during the validation
procedure, and the same procedure is used to monitor the
performance of the assay for each run. It is also recom-
mended that each lab engages in regular external quality
assurance programs.
Mutations with a variant allele frequency below 1%
should not be reported. The exact reportable range,
however, should be established and validated by each in-
dividual lab. Any variant should be reported, but those
for whom experimental or clinical information regarding
the sensitivity profile is available should be clearly
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distinguished from those with an unknown sensitivity/
resistance profile, and the TKIs not likely to be effective
against those mutants should be indicated, with refer-
ences to the existing literature.
Strength of the recommendations on indications of NGS
testing
The Panel discussed the issue of how binding clinical
centers that do not have access to NGS technology
should consider the indications for the use of NGS test-
ing for BCR-ABL1 KD mutation issued in this
document.
The Panel agreed that NGS testing should be encour-
aged in the proper indications for use in all the clinical
centers that care for patients with CML. However, the
Panel also argued that in no CML setting (CP, AP, BC)
has the lack of access to NGS testing been demonstrated
to hamper the possibility of properly managing CML pa-
tients. Thus, failure to perform an NGS test for BCR-
ABL1 KD mutations currently does not represent inappro-
priate clinical management of patients.
The Panel also suggested that NGS testing for BCR-
ABL1 KD mutations should be performed in a limited
number of highly specialized and qualified laboratories
within regional or national networks, undergoing peri-
odic and regular quality control rounds.
Discussion
BCR-ABL1 KD mutation testing is recommended both
by the ELN and by the NCCN in CML patients who do
not achieve an optimal response to TKI therapy. While
NCCN does not address any methodological aspect, the
ELN, in 2011, endorsed Sanger sequencing as the gold
standard for BCR-ABL1 KD mutation screening. The
ELN panel acknowledged that the limited sensitivity
(15–20%) of Sanger sequencing might be a drawback,
but admitted that Sanger sequencing was, at that time,
the only method enabling the scanning of the entire KD
for the multitude of mutations associated with imatinib
and second-generation TKI resistance [16]. At present,
however, an increasing number of laboratories are in the
process of implementing the NGS technology and inte-
grating NGS results into the diagnostic algorithms of
patients with various hematological malignancies. Over
the past five years, a series of studies exploring the use
of NGS for BCR-ABL1 mutation testing have assessed its
accuracy and reproducibility and have demonstrated that
it may provide a more accurate picture of KD mutation
status, which may better inform therapeutic decisions
[29–31, 34, 35, 38, 60, 62].
In this article, experts in CML judged whether the
body of evidence was sufficient to provide recommenda-
tions regarding the use of NGS for detecting low-level
mutations in the BCR-ABL1 transcript. Randomized
clinical trials assessing the advantage of a change of ther-
apy based on low-level mutations detectable by NGS (as
opposed to mutations detectable by Sanger, or as op-
posed to no mutation testing at all) are lacking. Thus,
the advantage of NGS-based treatment decision-making
has not yet been formally demonstrated. This forced the
Panel to use the method of consensus to shape the rec-
ommendations reported in this manuscript, and which
are summarized in Table 2.
After careful evaluation of the literature, the Panel rec-
ognized that the body of data available supports the use
of NGS in case of warning and failure responses to first-
or second-line therapy and in case of disease progression
from CP to AP or BC. In patients with warning, early
detection of an emerging TKI-resistant mutation may
play a key role in identifying those patients who might
benefit from a proactive TKI switch rather than from a
“wait-and-watch” approach. In patients with failure, it
has been shown that some cases may harbor mutations
below the lower detection limit of Sanger sequencing, and
that, even in Sanger sequencing-positive patients, add-
itional low-level mutations relevant for TKI selection may
be detectable by NGS. For patients receiving third-line
treatment and beyond, there are currently no formal defi-
nitions of failure and warning response, hence no pub-
lished NGS data. Nevertheless, it can be assumed that
NGS may equally be useful in patients who do not im-
prove their responses on third-line therapy or beyond, to
prevent them from continuing on an inappropriate ther-
apy. In patients who progress to AP or BC, multiple muta-
tions are often detectable [34]; in this setting, NGS may
provide a straightforward way to identify compound
mutants.
The Panel discussion also highlighted a series of scenar-
ios where very little data are available regarding the
frequency and clinical significance of mutations, either de-
tected with Sanger sequencing or NGS. They include the
setting of patients who present in AP or BC, the setting of
patients who lose MMR after TKI discontinuation or who
fail to regain MMR after therapy has been reintroduced,
and the post-SCT setting. Further studies are definitely
needed in those specific patient populations.
According to the ELN (and the European Society for
Medical Oncology [ESMO]) recommendations, detection
of a BCR-ABL1 KD mutation by Sanger sequencing de-
notes a failure of TKI therapy and mandates a change of
the therapeutic strategy [33, 65]. A variety of studies
comparing NGS and Sanger sequencing results have
shown that NGS and Sanger results are highly concord-
ant for all variants with a frequency of 15% or higher
[29–31, 34, 35, 38, 60, 66–72]. The clinical significance
of mutation loads between 1 and 15% has been shown
by some retrospective studies and, very recently, by a
prospective study in which a consecutive series of
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patients were monitored by NGS irrespective of their re-
sponse to the ongoing TKI therapy [29–31, 34]. More-
over, a recently completed prospective multicenter study
(“NEXT-in-CML”) has shown that low-level, known
TKI-resistant mutants identified by NGS remain consist-
ently detectable and increase in burden whenever the
TKI they are insensitive to is not changed [63]. In both
of these prospective studies, mutations between 1 and
3% were excluded because, in that range, some false
positive and false negative results were found to occur.
Thus, there are two critical issues around the relevance
of low-level mutations: on one hand, what is the “tech-
nical” threshold above which a true low-level mutation
(and not an amplification or sequencing artifact) can be
detected; on the other hand, what is the “clinical”
threshold above which a low-level mutation should be
incorporated into therapeutic decision algorithms. Both
are equally important, and both deserve further investi-
gation. Pragmatically, it is unlikely that a unique thresh-
old of significance can be defined and applied to all
mutations and to all patients. While the resistance pro-
file of some mutations is well established, for others
there are inconclusive in vitro sensitivity data, or even
no data at all. The latter might be passengers rather than
drivers and should not trigger an immediate change of
therapy in patients not exhibiting a clear “failure” re-
sponse. Besides this, in each individual case, NGS results
should be contextualized and integrated with disease-
and patient-specific characteristics and considerations.
In this light, and taking into account the uncertainty due
to the inherent error rate of the methodology, the Panel
agreed that for mutations detected with a frequency be-
tween 1 and 3%, validation and monitoring of mutation
kinetics in at least one subsequent sample collected in 1
month should be undertaken before taking any decision.
In the future, Digital PCR [18] might become the method
of choice for rapid and inexpensive orthogonal validation
of clinically relevant low-level mutations detected by NGS.
However, the existing commercial kits are not suitable for
the detection of mutations in BCR-ABL1 transcripts.
Finally, the Panel compiled a series of methodological
recommendations, defining the key features and minimal
performance characteristics for an NGS-based BCR-
ABL1 KD mutation testing assay. This was felt to be im-
portant since no commercial assays are yet available.
Thus, each laboratory will be responsible for the design,
set up and validation of its own, “home brew” protocol
as well as for the regular monitoring of assay perform-
ance. For the same reason, the Panel underlined the
importance that NGS be performed only by highly quali-
fied laboratories, belonging to specialized national or
international networks, ensuring continuous scientific
update and cooperating in the standardization of proto-
cols and periodical quality control rounds. Designation
of a few expert referral laboratories where samples can
be centralized will also be mandatory to ensure reason-
able costs and turnaround times.
Conclusions
Different situations in which NGS may be, to a greater de-
gree than Sanger sequencing, useful in the optimization of
the therapeutic strategies have been discussed by a Panel of
experts, and a consensus opinion has been reached. With
this, we did not mean to compete with or substitute for,
but rather to lay the foundations for, the international ef-
forts under the auspices of ELN or other expert networks,
that can be predicted to take the lead in the worldwide dis-
semination of clinical and technical recommendations re-
garding mutation testing in the near future. Of note, the
Panel pointed out that even though encouraged, NGS test-
ing cannot yet be considered mandatory in clinical practice,
so that lack of access to NGS cannot be claimed to result in
inappropriate patient management. However, the indica-
tions for the use of NGS described in this position paper
can be expected to improve CML diagnostics by encour-
aging more widespread use of NGS for detecting BCR-
ABL1 KD mutations while preventing unnecessary and/or
poor-quality testing. This will also foster the interaction be-
tween molecular pathology centers and provide a stepping-
stone towards a common NGS language between different
platforms and centers.
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